Pfizer (NYSE:PFE) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Pfizer (NYSE:PFE) released its earnings results on Tuesday. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08, Zacks reports. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer updated its FY 2025 guidance to 3.000-3.150 EPS.

Pfizer Stock Performance

Shares of PFE stock traded down $0.29 during mid-day trading on Tuesday, reaching $24.37. 95,925,720 shares of the company’s stock traded hands, compared to its average volume of 48,239,133. Pfizer has a 12 month low of $20.92 and a 12 month high of $28.00. The firm has a 50 day moving average price of $24.76 and a two-hundred day moving average price of $24.31. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market capitalization of $138.54 billion, a PE ratio of 12.98, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. Pfizer’s payout ratio is presently 91.49%.

Institutional Investors Weigh In On Pfizer

A number of hedge funds have recently modified their holdings of the business. Darwin Wealth Management LLC bought a new position in Pfizer in the 2nd quarter worth $32,000. WFA of San Diego LLC bought a new position in Pfizer in the 2nd quarter worth $40,000. WealthCollab LLC boosted its holdings in Pfizer by 12.5% in the 2nd quarter. WealthCollab LLC now owns 3,985 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 442 shares during the period. Binnacle Investments Inc boosted its holdings in Pfizer by 65.1% in the 2nd quarter. Binnacle Investments Inc now owns 5,752 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 2,267 shares during the period. Finally, State of Wyoming boosted its holdings in Pfizer by 77.8% in the 2nd quarter. State of Wyoming now owns 7,427 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 3,251 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. UBS Group restated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Morgan Stanley decreased their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.24.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.